You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大行評級 | 目標價82港元!中信證券首次覆蓋維昇藥業(2561.HK) 給予“買入”評級
格隆匯 05-23 10:53

中信證券發研究報告,首次覆蓋維昇藥業(2561.HK),給予“買入”評級,目標價82港元。該報告指出,公司爲內分泌領域的創新藥企,目前擁有三款產品,由Ascendis Pharma引入;Ascendis Pharma爲公司的深度合作夥伴,近期在美股市值爲100億美元左右,體現了市場對其核心技術平臺的高度認可。根據公司招股書,公司研發進展最快的是隆培促生長素(長效生長激素),公司預計在2025H2國內獲批上市;國內長效生長激素市場相對藍海,弗若斯特沙利文預測有望在 2030 年達到211億元,公司的產品優勢明顯,有望獲得較大的市場分額。目前,公司擁有2款獨特品種,分別爲那韋培肽和帕羅培特立帕肽,後者有望在2025年底遞交上市申請,一齊爲公司的長期增長提供驅動力。

該行給予維昇藥業“買入”評級,使用絕對估值法,通過DCF模型測算公司合理股權價值93.53億港元,對應2025年目標價82港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account